CV
What one share of CapsoVision holds
Electromedical and Electrotherapeutic Apparatus
We are a global commercial-stage medical technology company focused on creating diagnostic and screening products to identify abnormalities of the GI tract. We develop advanced imaging and AI technologies in creating such products while maximizing the flexibility, convenience, profitability, and safety of patient care.
CapsoVision’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.29 |
|---|---|
| Profit | −$0.62 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.58 |
| Book value | $0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2024 | $5.82 | −$9.85 | $0.08 | −$10.02 | — | −$61.94 |
| 2025 | $0.55 | −$1.03 | $0.00 | −$0.93 | — | $0.28 |